About Cytel Statistical Software & Services Pr Ivate Limited
Data last updated: 05 January 2026
Cytel Statistical Software & Services Pr Ivate Limited is a private limited company based in Pune, Maharashtra, India, a subsidiary of Cytel Inc. Usa. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 03 April 2001, the company has been in operation for over 25 years.
Registered with ROC Pune under CIN U72200PN2001PTC016025.
Capital: an authorised share capital of ₹10 Lakh and a paid-up capital of ₹3.05 Lakh. Formerly known as Someshwar Cement Pipe Company Private Limited and Quantlink Solutions Private Limited. It is led by directors including Santosh Sundar Shetty and Anagha Ajitkumar Chaphalkar.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: S.No.150 Lohia – Jain It Park A Wing 5Th Floor Office No. 501 Paud Road Kothrud, Pune, Maharashtra, India – 411038.
As per the financials filed for FY 2025, the company reported a revenue of ₹167.76 Cr, a growth of 8% compared to the previous year.
It operates as a subsidiary of Cytel Inc. Usa.
The company is associated with 1 brand - Cytel. As per MCA filings, the company has satisfied charges of ₹1 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cytel.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressS.No.150 Lohia – Jain It Park A Wing 5Th Floor Office No. 501 Paud Road Kothrud, Pune, Maharashtra, India – 411038
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Cytel Statistical Software & Services Pr Ivate Limited
Cytel Statistical Software & Services Pr Ivate Limited has undergone 2 name changes throughout its history. The company was previously known as Someshwar Cement Pipe Company Private Limited, and Quantlink Solutions Private Limited. The current legal name is Cytel Statistical Software & Services Pr Ivate Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Cytel Statistical Software & Services Pr Ivate Limited | Current |
| Someshwar Cement Pipe Company Private Limited | Previous |
| Quantlink Solutions Private Limited | Previous |
Associated Brands with Cytel Statistical Software & Services Pr Ivate Limited
Cytel Statistical Software & Services Pr Ivate Limited operates one associated brand: Cytel. These brands represent Cytel Statistical Software & Services Pr Ivate Limited's diversified market presence and brand portfolio.
Competitors & Alternatives of Cytel Statistical Software & Services Pr Ivate Limited
Brands and companies operating in the same space as Cytel Statistical Software & Services Pr Ivate Limited include DNAnexus, LabCorp, Charles River Laboratories and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
DNAnexus
|
Cloud-based genome informatics and data management are provided. | Mountain View, United States, United States | 2009 |
LabCorp
|
Provider of laboratory tests for physicians | Burlington, United States, United States | 1969 |
Charles River Laboratories
|
Provider of drug discovery and preclinical development services | Wilmington, United States, United States | 1947 |
Precision Medicine Group
|
Provider of clinical research, development, and commercialization services for life sciences | Bethesda, United States, United States | 2012 |
Precision for Medicine
|
Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices | Bethesda, United States, United States | 2013 |
Metagenomi
|
Next-generation gene editing tools are developed for drug enhancement. | Berkeley, United States, United States | 2016 |
Frontage Laboratories
|
Early drug development services are provided for pharma firms. | Exton, United States, United States | 2001 |
Canopy Biosciences
|
Cell line engineering services are offered via CRISPR-Cas9 technology. | St. Louis, United States, United States | 2016 |
Business Activity of Cytel Statistical Software & Services Pr Ivate Limited
Cytel Statistical Software & Services Pr Ivate Limited is engaged in the principal business activity of information and communication, with detailed activities including computer programming, consultancy and related activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| J | Information and communication | J6 | Computer programming, consultancy and related activities | ********* |
Auditor Details of Cytel Statistical Software & Services Pr Ivate Limited
Cytel Statistical Software & Services Pr Ivate Limited is audited by Suresh Surana & Associates Llp for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Suresh Surana & Associates Llp | blur-value | blur-value | blur-value |
Board of Directors of Cytel Statistical Software & Services Pr Ivate Limited
Cytel Statistical Software & Services Pr Ivate Limited is currently managed by 3 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Santosh Sundar Shetty | Director | 30 Sep 2022 | 3 Years 9 Months | Current |
|
Anagha Ajitkumar Chaphalkar
Also directs:
Avanti Mining Tools Pvt Ltd
|
Director | 25 Mar 2021 | 5 Years 3 Months | Current |
| Aniruddha Sudhakar Deshmukh | Director | 06 Mar 2023 | 3 Years 4 Months | Current |
Financials of Cytel Statistical Software & Services Pr Ivate Limited FY 2025 filings available
Cytel Statistical Software & Services Pr Ivate Limited reported revenue of ₹167.76 Cr (up 8% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Cytel Statistical Software & Services Pr Ivate Limited
As of FY 2023, Cytel Statistical Software & Services Pr Ivate Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Cytel Statistical Software & Services Pr Ivate Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Apr 2013 | Hdfc Bank Limited | ₹1 Cr | Satisfied |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Cytel Statistical Software & Services Pr Ivate Limited
View historical data on people associated with Cytel Statistical Software & Services Pr Ivate Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Cytel Statistical Software & Services Pr Ivate Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Cytel Statistical Software & Services Pr Ivate Limited
GSTIN & GST Filing Data of Cytel Statistical Software & Services Pr Ivate Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Cytel Statistical Software & Services Pr Ivate Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Cytel Statistical Software & Services Pr Ivate Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Cytel Statistical Software & Services Pr Ivate Limited
MSME Payment Delays by Cytel Statistical Software & Services Pr Ivate Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Cytel Statistical Software & Services Pr Ivate Limited
Subsidiaries & Group Companies of Cytel Statistical Software & Services Pr Ivate Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Cytel Statistical Software & Services Pr Ivate Limited with ownership details.
MCA Filings & Documents of Cytel Statistical Software & Services Pr Ivate Limited
MCA Filings & Documents of Cytel Statistical Software & Services Pr Ivate Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Cytel Statistical Software & Services Pr Ivate Limited
Recent News on Cytel Statistical Software & Services Pr Ivate Limited
Frequently Asked Questions about Cytel Statistical Software & Services Pr Ivate Limited
Cytel Statistical Software & Services Pr Ivate Limited is an active private limited company in the life sciences sector based in Pune, Maharashtra, India. It was incorporated on 03 April 2001 (25+ years old) and is registered under CIN U72200PN2001PTC016025.
Cytel Statistical Software & Services Pr Ivate Limited reported revenue of ₹167.76 Cr for FY 2025 (up 8.00% YoY).
The current directors of Cytel Statistical Software & Services Pr Ivate Limited are:
The primary industry of Cytel Statistical Software & Services Pr Ivate Limited is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Cytel Statistical Software & Services Pr Ivate Limited can be reached at the registered office: S.No.150 Lohia – Jain It Park A Wing 5Th Floor Office No. 501 Paud Road Kothrud, Pune, Maharashtra, India – 411038, or through the website cytel.com.
The authorised capital is ₹10 Lakh, and the paid-up capital is ₹3.05 Lakh.